<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Augmentation of cardiac sympathetic tone during <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e> has been shown to increase myocardial <z:chebi fb="0" ids="15379">O(2)</z:chebi> demand and <z:mpath ids='MPATH_124'>infarct</z:mpath> size as well as induce <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We have previously demonstrated that electroacupuncture (EA) inhibits the visceral sympathoexcitatory cardiovascular reflex </plain></SENT>
<SENT sid="2" pm="."><plain>The purpose of this study was to determine the effects of EA on left ventricular (LV) function, <z:chebi fb="0" ids="15379">O(2)</z:chebi> demand, <z:mpath ids='MPATH_124'>infarct</z:mpath> size, arrhythmogenesis, and in vivo cardiac <z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi> (NE) release in a <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e>-reperfusion model </plain></SENT>
<SENT sid="3" pm="."><plain>Anesthetized rabbits (n = 36) underwent 30 min of left anterior descending coronary <z:mp ids='MP_0006134'>artery occlusion</z:mp> followed by 90 min of reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain>We evaluated myocardial <z:chebi fb="0" ids="15379">O(2)</z:chebi> demand, <z:mpath ids='MPATH_124'>infarct</z:mpath> size, <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo>, and myocardial NE release using microdialysis under the following experimental conditions: 1) untreated, 2) EA at P5-6 acupoints, 3) sham acupuncture, 4) EA with pretreatment with <z:chebi fb="1" ids="7459">naloxone</z:chebi> (a nonselective opioid receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>), 5) EA with pretreatment with chelerythrine (a nonselective PKC inhibitor), and 6) EA with pretreatment with both <z:chebi fb="1" ids="7459">naloxone</z:chebi> and chelerythrine </plain></SENT>
<SENT sid="5" pm="."><plain>Compared with the untreated and sham acupuncture groups, EA resulted in decreased <z:chebi fb="0" ids="15379">O(2)</z:chebi> demand, myocardial NE concentration, and <z:mpath ids='MPATH_124'>infarct</z:mpath> size </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, the degree of ST segment elevation and severity of LV dysfunction and <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> were <z:hpo ids='HP_0000001'>all</z:hpo> significantly decreased (P &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>The cardioprotective effects of EA were partially blocked by pretreatment with <z:chebi fb="1" ids="7459">naloxone</z:chebi> or chelerythrine alone and completely blocked by pretreatment with both <z:chebi fb="1" ids="7459">naloxone</z:chebi> and chelerythrine </plain></SENT>
<SENT sid="8" pm="."><plain>These results suggest that the cardioprotective effects of EA against <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e>-reperfusion are mediated through inhibition of the cardiac sympathetic <z:mp ids='MP_0008912'>nervous</z:mp> system as well as opioid and PKC-dependent pathways </plain></SENT>
</text></document>